Paper Details

  1. Home
  2. Paper Details

Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.

Author: LentzschSuzanne, RazaShahzad, SafyanRachael A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review discusses the current therapeutic approach to multiple myeloma, highlighting the role of immunomodulatory drugs and proteasome inhibitors in improving overall survival.
Paper Details　
Original Abstract of the Article :
Multiple myeloma (MM) is a hematological cancer caused by a proliferation of clonal plasma cells, leading to anemia, renal failure, hypercalcemia and destructive bone lesions resulting in significant morbidity. The overall survival has significantly improved with the incorporation of immunomodulator...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/1568009617666170214104426

データ提供：米国国立医学図書館（NLM）

IMiDs: A New Weapon in the Fight Against Multiple Myeloma

Multiple myeloma, a cancer of plasma cells in the bone marrow, presents a formidable challenge to medical professionals. This research explores the role of immunomodulatory drugs (IMiDs) in the treatment of multiple myeloma. This research is like a skilled archer, aiming to target and neutralize the cancer cells.

A New Era of Treatment: IMiDs and Proteasome Inhibitors

The researchers highlight the significant improvements in overall survival for patients with multiple myeloma due to the introduction of IMiDs and proteasome inhibitors. These drugs work by modulating the immune system and targeting specific pathways involved in cancer cell survival. This research is like a desert oasis, offering hope and relief to patients facing a challenging diagnosis.

A Beacon of Hope: New Therapies for Multiple Myeloma

This research provides a ray of hope for individuals diagnosed with multiple myeloma, offering a glimpse of a brighter future with improved treatment options. This research emphasizes the ongoing quest for new therapies to combat cancer, reminding us that even in the face of adversity, progress is always possible.

Dr.Camel's Conclusion

This research is a testament to the tireless efforts of researchers to develop innovative therapies for cancer. The introduction of IMiDs and proteasome inhibitors has significantly improved outcomes for patients with multiple myeloma, offering a beacon of hope in the fight against this challenging disease. This progress is a reminder that even in the harshest of deserts, life finds a way to thrive.

Date :
  1. Date Completed 2018-06-13
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28201976

DOI: Digital Object Identifier

10.2174/1568009617666170214104426

Related Literature

Article Analysis
・Side Effects of pomalidomide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.